“…Myeloid/classic DC, plasmacytoid DC, monocyte-related DC, and Langerhans cell subtypes exert divergent biological effects as antigen presenting cells, including differential capacity for cross presentation, 24 cytokine production, and polarization toward Th1, Th2, Th17, or regulatory T cell (Treg) immunophenotypes under the influence of various microbiological and biochemical stimuli 25, 26, 27, 28. Each of these alternative DC subtypes, including Langerhans cells,29, 30, 31 DCs derived from CD34-positive umbilical cord blood progenitor cells,32, 33, 34, 35 and plasmacytoid DCs36, 37, 38, 39 have been explored for use in DC vaccine development in different solid and hematologic malignancies.…”